Structural proteomics: The potential of high-throughput structure determination

Trends in Microbiology

Volumn 10, Issue 10, 2002, Pages

  Schmid, Molly B ^a  

^a Affinium Pharmaceuticals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

CAENORHABDITIS ELEGANS; DROSOPHILA MELANOGASTER; DRUG INDUSTRY; DRUG STRUCTURE; DRUG TARGETING; GENOMICS; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA GENITALIUM; MYCOPLASMA PNEUMONIAE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEOMICS; PROTOZOON; REVIEW; SACCHAROMYCES CEREVISIAE; THERMUS THERMOPHILUS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CRYSTALLOGRAPHY; DRUG DESIGN; GENOMICS; IMAGING, THREE-DIMENSIONAL; MOLECULAR STRUCTURE; PEPTIDE MAPPING; PROTEIN CONFORMATION; PROTEOMICS; TECHNOLOGY, PHARMACEUTICAL;

CAENORHABDITIS; CAENORHABDITIS ELEGANS; DROSOPHILA MELANOGASTER; MELANOGASTER; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA; MYCOPLASMA GENITALIUM; MYCOPLASMA PNEUMONIAE; PROTOZOA; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE; THERMUS; THERMUS THERMOPHILUS;

EID: 0036791908     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(02)02443-5     Document Type: Review

References (38)

1. De Clercq E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 1:2002;13-25.
2. Judson N., Mekalanos J.J. Transposon-based approaches to identify essential bacterial genes. Trends Microbiol. 8:2000;521-526.
3. Schmid M.B. Novel approaches to the discovery of antimicrobial agents. Curr. Opin. Chem. Biol. 2:1998;529-534.
4. DeVito J.A., et al. An array of target-specific screening strains for antibacterial discovery. Nat. Biotechnol. 20:2002;478-483.
5. Zhang L., et al. Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene. 255:2000;297-305.
6. Christensen D.J., et al. Phage display for target-based antibacterial drug discovery. Drug Discov. Today. 6:2001;721-727.
7. McDevitt D., et al. Novel targets for the future development of antibacterial agents. J. Appl. Microbiol. 92:(Suppl):2002;S28-S34.
8. McDevitt D., Rosenberg M. Exploiting genomics to discover new antibiotics. Trends Microbiol. 9:2001;611-617.
9. Vitkup D., et al. Completeness in structural genomics. Nat. Struct. Biol. 8:2001;559-566.
10. Zemla A., et al. Processing and evaluation of predictions in CASP4. Proteins. 45:(Suppl. 5):2001;13-21.
11. Stevens R.C. Design of high-throughput methods of protein production for structural biology. Structure Fold Des. 8:2000;R177-R185.
12. Lesley S.A. High-throughput proteomics: protein expression and purification in the postgenomic world. Protein Expr. Purif. 22:2001;159-164.
13. Edwards A.M., et al. Protein production: feeding the crystallographers and NMR spectroscopists. Nat. Struct. Biol. 7:(Suppl):2000;970-972.
14. Gilbert M., Albala J.S. Accelerating code to function: sizing up the protein production line. Curr. Opin. Chem. Biol. 6:2002;102-105.
15. Stevens R.C., et al. Global efforts in structural genomics. Science. 294:2001;89-92.
16. Christendat D., et al. Structural proteomics of an archaeon. Nat. Struct. Biol. 7:2000;903-909.
17. Chance M.R., et al. Structural genomics: a pipeline for providing structures for the biologist. Protein Sci. 11:2002;723-738.
18. Yee A., et al. An NMR approach to structural proteomics. Proc. Natl. Acad. Sci. U. S. A. 99:2002;1825-1830.
19. Hammarstrom M., et al. Rapid screening for improved solubility of small human proteins produced as fusion proteins in Escherichia coli. Protein Sci. 11:2002;313-321.
20. Rayment I. Small-scale batch crystallization of proteins revisited: an underutilized way to grow large protein crystals. Structure. 10:2002;147-151.
21. Chayen N.E., Saridakis E. Protein crystallization for genomics: towards high-throughput optimization techniques. Acta Crystallogr. D. Biol. Crystallogr. 58:2002;921-927.
22. Villasenor A., et al. Fast drops: a high-throughput approach for setting up protein crystal screens. BioTechniques. 32:2002;184-189.
23. Bertone P., et al. SPINE: an integrated tracking database and data mining approach for identifying feasible targets in high-throughput structural proteomics. Nucleic Acids Res. 29:2001;2884-2898.
24. Abola E., et al. Automation of X-ray crystallography. Nat. Struct. Biol. 7:(Suppl):2000;973-977.
25. Ealick S.E. Advances in multiple wavelength anomalous diffraction crystallography. Curr. Opin. Chem. Biol. 4:2000;495-499.
26. Campbell I.D. Timeline: the march of structural biology. Nat. Rev. Mol. Cell Biol. 3:2002;377-381.
27. Abagyan R., Totrov M. High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 5:2001;375-382.
28. Hooper D.C. Mode of action of fluoroquinolones. Drugs. 58:(Suppl. 2):1999;6-10.
29. Trias J. The role of combichem in antibiotic discovery. Curr. Opin. Microbiol. 4:2001;520-525.
30. Miller W.H., et al. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem. 45:2002;3246-3256.
31. Yusupov M.M., et al. Crystal structure of the ribosome at 5.5 Å resolution. Science. 292:2001;883-896.
32. Ban N., et al. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution. Science. 289:2000;905-920.
33. Murakami K.S., et al. Structural basis of transcription initiation: RNA polymerase holoenzyme at 4 Å resolution. Science. 296:2002;1280-1284.
34. Murakami K.S., et al. Structural basis of transcription initiation: an RNA polymerase holoenzyme-DNA complex. Science. 296:2002;1285-1290.
35. Guilloteau J.P., et al. The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J. Mol. Biol. 320:2002;951-962.
36. Wei Y., et al. Identification of a potent peptide deformylase inhibitor from a rationally designed combinatorial library. J. Comb. Chem. 2:2000;650-657.
37. Thorarensen A., et al. Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Bioorg. Med. Chem. Lett. 11:2001;1355-1358.
38. Apfel C., et al. 2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2(6-benzo [1,2,6] thiadiazin-3-yl)-N-hydrox y-acetamides as potent and selective peptide deformylase inhibitors. J. Med. Chem. 44:2001;1847-1852.